NASDAQ:ARIA - Nasdaq - US04033A1007
23.99
+0.04 (+0.17%)
The current stock price of ARIA is 23.99 null. In the past month the price increased by 1.24%. In the past year, price increased by 368.56%.
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.
ARIAD PHARMACEUTICALS INC
26 LANDSDOWNE ST
CAMBRIDGE MA 02139
CEO: Paris Panayiotopoulos
Phone: 617-494-0400
The current stock price of ARIA is 23.99 null. The price increased by 0.17% in the last trading session.
The exchange symbol of ARIAD PHARMACEUTICALS INC is ARIA and it is listed on the Nasdaq exchange.
ARIA stock is listed on the Nasdaq exchange.
ARIAD PHARMACEUTICALS INC (ARIA) has a market capitalization of 4.66B null. This makes ARIA a Mid Cap stock.
ARIAD PHARMACEUTICALS INC (ARIA) has a support level at 23.87 and a resistance level at 24. Check the full technical report for a detailed analysis of ARIA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARIA does not pay a dividend.
ARIAD PHARMACEUTICALS INC (ARIA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
ChartMill assigns a technical rating of 10 / 10 to ARIA. When comparing the yearly performance of all stocks, ARIA is one of the better performing stocks in the market, outperforming 99.41% of all stocks.
Over the last trailing twelve months ARIA reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -916.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 101.23% | ||
ROA | -5.12% | ||
ROE | 0% | ||
Debt/Equity | N/A |